BRIEF-Eiger announces first patient dosed in open-label extension of phase 2 liberty study of ubenimex
January 03, 2017 at 08:11 AM EST
* Eiger announces first patient dosed in open-label extension of phase 2 liberty study of Ubenimex in pulmonary arterial hypertension (pah) Source text for Eikon: Further company coverage:
